Beactica Takes Major Step Forward with First Advisory Meeting on BEA-17

Beactica Conducts First Advisory Meeting on BEA-17

On October 7, 2025, Beactica Therapeutics AB, a leading Swedish precision medicine company, announced a significant milestone in the development of its drug candidate, BEA-17. The meeting took place with the Swedish Medical Products Agency (MPA) and aimed to outline the preclinical objectives required for transitioning BEA-17 into human trials.

Dr. Per Källblad, CEO of Beactica, expressed the significance of this initial encounter with regulatory authorities, stating, "It is an important milestone for BEA-17 and Beactica to have completed the first formal meeting with regulatory authorities. It was a successful meeting where we received support for our plans, and we now have a clear picture of what needs to be done in the continued work towards a planned clinical trial application."

About BEA-17

BEA-17 stands out as a first-of-its-kind small molecule aimed specifically at degrading lysine demethylase 1 (LSD1) along with its co-factor, CoREST. Remarkably, clinical evaluations in syngeneic animal models of cancer have demonstrated that BEA-17 amplifies the effects of immune-modulating therapies. This includes its potent synergy with anti-PD1 checkpoint inhibitors in models of colon cancer (CT26) and its potential compatibility with standard treatment regimens for glioblastoma involving temozolomide and radiation (GL261).

Pharmacokinetic studies reveal that BEA-17 is capable of effectively crossing the blood-brain barrier, ensuring appropriate oral availability—a vital characteristic for its role in cancer treatment. However, it is essential to note that BEA-17 remains an investigational compound and has not yet received global approval. Currently, its efficacy and safety profiles in humans have yet to be established. Nonetheless, notable recognition has been granted by the U.S. Food and Drug Administration (FDA), with BEA-17 designated as an Orphan Drug for the treatment of glioblastoma (GBM).

About Beactica Therapeutics

Beactica Therapeutics AB operates as a privately held precision medicine entity, focusing on novel small molecule therapeutics aimed at fulfilling significant medical needs. The company's mission revolves around the innovative Eclipsor™ platform, which facilitates the efficient development of allosteric modulators and targeted protein degraders. By advancing its programs to clinical proof of concept, Beactica aims to deliver impactful solutions for patients as well as substantial value for its shareholders.

Through this recent advisory meeting with the Swedish Medical Products Agency, Beactica positions itself for potential breakthroughs in precision medicine treatments, especially in oncology. As the journey towards human trials for BEA-17 unfolds, both the scientific community and cancer patients alike will be observing the progress with keen interest. The successful outreach to regulatory bodies reinforces Beactica's commitment to bringing innovative therapies to market.